|
000
| 02050cam 2200313za 4500 |
|---|
| 001 | 9.836313 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107150854 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 180201s2017 onc ob f000 0 eng d |
|---|
| 020 | |a978-0-660-08486-2 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aHP40-1/2017-3E-PDF |
|---|
| 245 | 00|aCanadian guidelines on sexually transmitted infections |h[electronic resource] : |btreatment of N. gonorrhoeae in response to the discontinuation of spectinomycin : alternative treatment guidance statement. |
|---|
| 246 | 30|aTreatment of N. gonorrhoeae in response to the discontinuation of spectinomycin : |balternative treatment guidance statement |
|---|
| 260 | |a[Ottawa] : |bPublic Health Agency of Canada, |c2017. |
|---|
| 300 | |a4 p. |
|---|
| 500 | |aCaption title. |
|---|
| 500 | |a"May 2017." |
|---|
| 504 | |aIncludes bibliographical references. |
|---|
| 520 | |a“The Public Health Agency of Canada (PHAC) has been informed that manufacturing of spectinomycin has been discontinued. This antimicrobial is therefore no longer available through Health Canada’s Special Access Program (SAP). In the face of increasing antimicrobial resistance in Neisseria gonorrhoeae, the discontinuation of spectinomycin has the potential to limit gonorrhea prevention and control efforts in Canada by further restricting treatment options. This guidance statement for alternative treatments for gonococcal infections was developed in consultation with the CGSTI Expert Working Group based on Canadian epidemiology and a rapid evidence review”--Issue, p. 1. |
|---|
| 692 | 07|2gccst|aSexually transmitted diseases |
|---|
| 692 | 07|2gccst|aMedicine |
|---|
| 692 | 07|2gccst|aGuidelines |
|---|
| 710 | 2 |aPublic Health Agency of Canada. |
|---|
| 775 | 08|tLignes directrices canadiennes sur les infections transmissibles sexuellement. |w(CaOODSP)9.836314 |
|---|
| 794 | |tCanadian guidelines on sexually transmitted infections |w(CaOODSP)9.840166 |
|---|
| 856 | 40|qPDF|s364 KB|uhttps://publications.gc.ca/collections/collection_2018/aspc-phac/HP40-1-2017-3-eng.pdf |
|---|